- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05530707
Evaluation of Acceptability, Skin Barrier Restoration and Balance of Atopic Skin Using Moisturizer
Avaliação de Aceitabilidade dérmica, eficácia Hidratante, restauração da Barreira e equilíbrio da Microbiota da Pele atópica de um Produto Hidratante - Estudo Clínico, Instrumental e Subjetivo.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A unicentric, blind, non-comparative clinical study to evaluate the efficacy of a moisturizer in reducing clinical symptons of atopic skin dermatites in children through clinical, subjective and instrumental evaluations.
Participants will be divided into 2 groups - (Group 1) Microbiome analysis; and (Group 2) Acceptabily and efficacy
Group 1: It will be necessary 13 participants aged between 05 and 12 years old with historical of atopia
The participant will remain in the study for 30 days using the product. Visits will be scheduled in D0 and D30. On both visits, samples will be collect to quantify Staphylococcus aureus using qPCR
Group 2: It will be necessary 36 participants aged between 05 and 12 years old with historical of atopia
The participant will remain in the study for 60 days using the product. Visits will be scheduled in D0, D7, D30 and D60.
Instrumental evaluations: It will be evaluate on each visit:
Skin hidration using Corneometer - D0, D7, D30, D60 Transepidermic water loss using TEWL - D0, D7, D30, D60 Skin barrier restoration using Confocal Microscopy - D0, D30, D60
Participants will respond to a subjective assessment using a questionnaire to capture possible feelings of discomfort during the study e subjective efficiency.
A dermatologist will be available to monitor the participants throughout the study and respond a assessment of clinical efficiency.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
São Paulo
-
Osasco, São Paulo, Brazil, 06023-000
- Medcin Instituto Da Pele
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Understand and consent to participation in this clinical trial, manifested through the signatures of the Informed Consent (TCLE) by at least one of the minor's legal guardians, and signature of the Free and Informed Consent Term (TALE) by the minor, when applicable (≥07 years);
- Agreement to participate the procedures and requirements of the study and attend the Institute on the day(s) and time(s) determined for the assessments accompanied by the responsible
- Participants with a history of atopy
- Participants with presence of dry skin with dryness, flaking and mild itching in the pretibial region
- Presence of active lesions of atopic dermatitis in the cubital cavus region for group 1 of participants who did not need other topical treatments besides the moisturizer
Exclusion Criteria:
- Pregnancy/lactation or intention to become pregnant during the study period;
- Presence of active lesions of atopic dermatitis for group 2 of participants - Clinical study;
- Use of the following topical or systemic medications: immunosuppressants, antihistamines, anti-inflammatory drugs corticosteroids up to 30 days prior to selection. For immunosuppressants, the interval should be 3 months prior to selection;
- Presenting or having a history of other concomitant skin conditions (e.g., psoriasis or lupus erythemasus) that interferes with the evaluations of the effect of the investigational product of the study on AD;
- Participants currently presenting a skin infection requiring treatment or are currently in need of treatment with topical or systemic antibiotics;
- Any serious concomitant disease in which the need for the use of systemic corticosteroids is expected or which, otherwise interfere with study participation or require frequent active monitoring (e.g., asthma chronicunstable);
- Unable or unwilling to be available throughout the study and/or not be willing to follow the study restrictions/procedures;
- Stomach diseases such as gastritis and ulcers;
- Chronic use of corticosteroids (systemic or topical);
- Chronic kidney diseases, chronic liver diseases;
- Clinical evidence of immunosuppression;
- Allergic history of category products;
- Participants with known congenital or acquired immunodeficiency;
- Relevant clinical history or current evidence of alcohol or other drug abuse;
- known history or suspected intolerance of products of the same category;
- Intense sun exposure up to 30 days before evaluation;
- Professionals directly involved in the present study;
- Other conditions considered by the evaluating physician as reasonable for disqualification from the participation of the study. If yes, it should be described under observation in the clinical file.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Microbiome
13 participants using the product for 30 days.
Aims to evaluate the quantification of S. Aureus in the skin before and after usage.
|
Moisturizer containing saccharide isomerate and niacinamide
|
Experimental: Clinical Trial
36 participants using the product for 60 days.
Aims to evaluate the clinical, subjective and instrumental usage.
|
Moisturizer containing saccharide isomerate and niacinamide
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Acceptability in real conditions of use by questionnaire
Time Frame: Day 60
|
Confirm in real conditions of use, the absence of risk and irritation and capture feelings of discomfort in the population studied (0 meaning no risk).
|
Day 60
|
Change of qPCR quantification of Staphylococcus aureus
Time Frame: Change from Baseline (Day 0) and day 30
|
Evaluate the change in the skin microbiota by quantification of qPCR of Staphylococcus aureus in the skin before (D0) and after 30 (D30) days of continuous use of the product.
|
Change from Baseline (Day 0) and day 30
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical Evaluation through dermatological questionnaire
Time Frame: Day 60
|
Evaluate the efficacy in reducing the signs of atopic dermatitis through dermatological clinical evaluation after 60 days of continuous use of the product
|
Day 60
|
Increase of skin hidration using instrumental evaluation - Corneometer
Time Frame: Day 0, 7, 30 and 60
|
Evaluate the moisturizing efficacy immediately (D0) after application of the investigational product and after 7 (D7), 30 (D30) and 60 (D60) days of continuous use, through the Corneometer equipment®
|
Day 0, 7, 30 and 60
|
Evaluation of recovery of skin barrier through instrumental method - TEWL
Time Frame: Day 7, 30 and 60
|
Evaluate the efficacy in the recovery of the skin barrier after 7 (D7), 30 (D30) and 60 (D60) days of continuous use of the product through the Tewameter equipment®
|
Day 7, 30 and 60
|
Strengthening of the skin barrier
Time Frame: Day 0, 30 and 60
|
Evaluate the strengthening of the skin barrier in D0 and after 30 (D30) and 60 (D60) days of continuous use of the product by confocal reflectance microscopy
|
Day 0, 30 and 60
|
Subjective efficacy from the participants
Time Frame: Day 0, 7, 30 and 60
|
Evaluate the perceived efficacy of the product from the participant's point of view through a subjective questionnaire immediately after the first application (Timed) and after 7 (D7), 30 (D30) and 60 (D60) days of continuous use of the product
|
Day 0, 7, 30 and 60
|
Improvement of Quality of Life
Time Frame: Day 0, 7, 30 and 60
|
Evaluate the improvement of the quality of life of the atopic dermatitis carrier through a questionnaire on quality of life in D0 and after 30 and 60 days of continuous use of the product
|
Day 0, 7, 30 and 60
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- EN21-0556-01_EN22-2004-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Sharing Time Frame
IPD Sharing Supporting Information Type
- Study Protocol
- Statistical Analysis Plan (SAP)
- Clinical Study Report (CSR)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atopic Dermatitis
-
Catalysis SLCompletedAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related Conditions | Atopic Dermatitis \(AD\)Serbia
-
Jacob Pontoppidan ThyssenThe Novo Nordic FoundationRecruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis FlareDenmark
-
ShaperonRecruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis of ScalpUnited States
-
University of California, San FranciscoSanofi; Regeneron PharmaceuticalsRecruitingEczema | Atopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related ConditionsUnited States
-
PfizerActive, not recruitingEczema | Atopic Dermatitis | Eczema, Atopic | Atopic Dermatitis, UnspecifiedUnited States, Canada, Czechia, Poland
-
AmgenCompletedDermatitis, Atopic DermatitisCanada, United States, Japan
-
Hadassah Medical OrganizationUnknownATOPIC DERMATITIS
-
National Institute of Allergy and Infectious Diseases...Atopic Dermatitis Research NetworkCompletedAtopic Dermatitis (AD) | Non-atopic Healthy ControlsUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...ZonMw: The Netherlands Organisation for Health Research and DevelopmentRecruitingAtopic Dermatitis | Atopic Dermatitis EczemaNetherlands
-
AbbVieActive, not recruiting
Clinical Trials on Moisturizer containing saccharide isomerate and niacinamide
-
Integrative Skin Science and ResearchSytheon Ltd.Completed
-
Mahidol UniversityBeiersdorfCompletedAcne Vulgaris | AcneThailand
-
Elmore Oil Company Pty LtdCompletedInflammation | Degenerative ArthritisPhilippines